Professor Grant McArthur

Grant McArthur completed his Bachelor of Medicine and Bachelor of Surgery at Monash University, graduating in 1985 with first class honours and being awarded the Australian Medical Association Prize for highest aggregate marks in final examinations for M.B.B.S.
He trained as a medical oncologist at Alfred Health and undertook a PhD in Experimental Haematology with Prof Donald Metcalf at the Walter and Eliza Hall Institute of Medical Research. Following award of his Fellowship of the Australian College of Physicians Prof McArthur then undertook post-doctoral studies at the Fred Hutchinson Cancer Centre in Seattle focusing on oncogenes and tumour suppressor genes.
On his return to Australia, Prof McArthur was appointed as a Consultant Medical Oncologist and Head, Molecular Oncology Laboratory and subsequently as the Head of the Cancer Therapeutics Program at the Peter MacCallum Cancer Centre. In 2014, Prof McArthur was appointed as the Inaugural Lorenzo Galli Chair of Melanoma & Skin Cancers at University of Melbourne, and in 2017 the Executive Director of the VCCC Alliance.

Professor McArthur was the inaugural winner of the Translational Research Award of the Foundation Nelia et Amadeo Barletta, has held the Sir Edward Dunlop Clinical Cancer Research Fellowship of the Cancer Council of Victoria, was awarded the inaugural Martin Lackmann medal for translational research, elected as a Fellow of the Australian Academy of Health & Medical Sciences, received the Medical Oncology Group of Australia’s Novartis Oncology Cancer Achievement Award and has been the recipient of the Tom Reeve Award from the Clinical Oncology Society of Australia.

Professor McArthur has published over 300 peer-reviewed papers, many in high impact journals, and has over 70,000 career citations. The focus of his scientific career has been on developing novel therapies for cancer based on understanding the oncogenic drivers of malignancies, and he has been global Principal Investigator on a number of early phase and practice-changing trials in cancer targeting BRAF, KIT and PDGF receptors. He now leads the VCCC Alliance, an organisation focused on improving cancer outcomes through research-led innovation in clinical care and education as Executive Director.